GlassScriptPhysician profile
David J Dipiazza
NPI 1356347280
$8,693.64
in general payments reported to CMS, 2019-2025
54 companies · $1,757 in 2025
The $1,757 reported for 2025 was more than what 77% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $1,184 · 2021: $876 · 2022: $1,189 · 2023: $1,723 · 2024: $1,158 · 2025: $1,757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,590 · Gift: $25.48 · Education: $22.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,590.00 |
| Gift | $25.48 |
| Education | $22.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,590.53 | 2020-2024 | Axonics, Bulkamid |
| Teleflex LLC | $668.93 | 2023-2025 | Barrigel, Urolift, Solesta |
| Neotract INC. | $545.24 | 2019-2020 | |
| Caldera Medical, INC | $501.59 | 2021-2025 | Desara |
| Abbvie INC. | $431.88 | 2020-2025 | Botox, Lupron Depot |
| Sumitomo Pharma America, INC. | $385.46 | 2023-2025 | Gemtesa, Orgovyx |
| Medtronic, INC. | $307.87 | 2021-2025 | Interstim, Nuro |
| Boston Scientific Corporation | $299.50 | 2019-2025 | Axonics |
| Astellas Pharma US INC | $291.92 | 2019-2025 | Xtandi |
| Urogen Pharma, INC. | $266.66 | 2023-2025 | Jelmyto |
| Coloplast Corp | $265.38 | 2019-2025 | Altis |
| Endo Pharmaceuticals INC. | $223.12 | 2020-2023 | Xiaflex, Aveed, Edex |
| Dendreon Pharmaceuticals LLC | $159.61 | 2019-2025 | Provenge |
| Amgen INC. | $155.30 | 2019-2022 | |
| Palette Life Sciences, INC. | $153.89 | 2022 |
Show all 52 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$66,817.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dipiazza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.